

***Fiscal Year 2022 Department of Defense Ovarian Cancer Research Program (OCRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Pilot Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-22-OCRP-PA</p>	<p>Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the Principal Investigator (PI) on the application.</p>	<ul style="list-style-type: none"> <li>• Supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.</li> <li>• Innovation and Impact are important review criteria.</li> <li>• The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects; thus, preliminary data are not required but are allowed.</li> <li>• Clinical trials are not allowed.</li> <li>• <b><i>Pre-application is required and is blinded; application is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$250,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 2, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 5, 2022 11:59 p.m. Eastern time</p>
<p><b>Proteogenomics Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-22-OCRP-PGRA</p>	<p>Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the PI on the application.</p>	<ul style="list-style-type: none"> <li>• Supports the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.</li> <li>• Innovation and impact are important review criteria.</li> <li>• Analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.</li> <li>• Clinical trials are not allowed.</li> <li>• Preliminary data are not required but are allowed.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$250,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 2, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 5, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Ovarian Cancer Academy – Early-Career Investigator Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-22-OCRP-OCAA</p>	<p>Must be within 5 years of last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent as of the full application submission deadline.</p> <p>A Statement of Eligibility is required with the submission of the full application.</p>	<ul style="list-style-type: none"> <li>• The OCRP Ovarian Cancer Academy is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty.</li> <li>• Early-Career Investigators whose ability to commit to conducting ovarian cancer research is limited by minimal resources or lack of resources or other overwhelming obstacles are encouraged to apply.</li> <li>• A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.</li> <li>• A Designated Mentor may only mentor one Early-Career Investigator.</li> <li>• The Designated Mentor is not required to be at the same institution as the Early-Career Investigator.</li> <li>• Preliminary data are required.</li> <li>• Clinical trials are allowed.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$725,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 2, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 5, 2022 11:59 p.m. Eastern time</p>
<p><b>Investigator-Initiated Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-22-OCRP-IIRA</p>	<p>Must be an independent investigator at or above the level of Assistant Professor (or equivalent).</p> <p>Partnering PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.</p>	<ul style="list-style-type: none"> <li>• Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.</li> <li>• Impact is an important review criterion.</li> <li>• Preliminary data are required.</li> <li>• Clinical trials are not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$600,000</b> for direct costs.</li> <li>• Maximum funding of <b>\$800,000</b> for direct costs (plus indirect costs) for the Partnering PI Option.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 2, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 5, 2022 11:59 p.m. Eastern time</p>